All > Paid Studies Houston > Maryland

CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T Cell (ARC-T Cells) for Acute Myeloid Leukemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Acute Myeloid Leukemia+1 MoreARC-T Cells - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

Eligible Conditions
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
DVX201
1
BAFFR-CAR T cells
1
KITE-222

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 24 months

24 months
Adverse Events and Dose-Limiting Toxicities
Anti-Tumor Activity
Anti-tumor activity
Incidence of treatment-emergent adverse events (TEAEs), including dose-limiting toxicities (DLTs) and establish recommended Phase II dose (RP2D)
Pharmacokinetics (PK)
Pharmacokinetics (PK) profile

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
DVX201
1
BAFFR-CAR T cells
1
KITE-222

Trial Design

1 Treatment Group

CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T Cell (ARC-T Cells)
1 of 1

Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T Cell (ARC-T Cells) · No Placebo Group · Phase 1

CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T Cell (ARC-T Cells)Experimental Group · 3 Interventions: ARC-T Cells, SPRX002, ARC-T · Intervention Types: Biological, Biological, Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

Arcellx, Inc.Lead Sponsor
2 Previous Clinical Trials
175 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be at least 18 years old.
You have been treated for AML with one or more standard treatments and have relapsed or refractory disease after 1 or 2 lines of therapy.
You have a performance status of 0 or 1.
You have adequate renal and hepatic function.
Creatinine clearance ≥50 ml/min (Cockcroft-Gault or 24-hour urine collection in cases in which Cockroft-Gault is unreliable or if preferred by physician) and not on dialysis.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top